Regulation of Bone Metabolism by Sex Steroids

Sundeep Khosla and David G. Monroe

Robert and Arlene Kogod Center on Aging and Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905
Correspondence: khosla.sundeep@mayo.edu

Osteoporosis is a significant public health problem, and a major cause of the disease is estrogen deficiency following menopause in women. In addition, considerable evidence now shows that estrogen is also a major regulator of bone metabolism in men. Since the original description of the effects of estrogen deficiency on bone by Fuller Albright more than 70 years ago, there has been enormous progress in understanding the mechanisms of estrogen and testosterone action on bone using human and mouse models. Although we understand more about the effects of estrogen on bone as compared with testosterone, both sex steroids do play important roles, perhaps in a somewhat compartment-specific (i.e., cancellous vs. cortical bone) manner. This review summarizes our current knowledge of sex steroid action on bone based on human and mouse studies, identifies both agreements and potential discrepancies between these studies, and suggests directions for future research in this important area.

Osteoporosis is a significant and growing public health problem; in fact, the number of women who will experience a fracture in one year exceeds the combined number of women who will experience incident breast cancer, myocardial infarction, or stroke (Cauley et al. 2008). The major trigger for the development of osteoporosis in women is the onset of estrogen deficiency following menopause (Riggs et al. 2002). Although men also develop osteoporosis with aging, they lack the abrupt cessation of gonadal function present in women. Nonetheless, considerable evidence indicates that even in men, declining sex steroid levels with aging, particularly declining bioavailable estrogen levels, contribute to age-related bone loss (Khosla et al. 2008). Thus, a better understanding of how sex steroids regulate bone metabolism is critical not only from a biological but also a clinical perspective.

Seminal studies by Fuller Albright more than 70 years ago showed that loss of estrogen following oophorectomy or menopause led to rapid bone loss and that calcium balance could be improved in postmenopausal women with estrogen treatment (Albright 1940). Decades later, Stepan and colleagues (1989) showed that, following castration, men also experienced similar rapid bone loss; because testosterone is the major sex steroid in men, this led to the longstanding dogma that estrogen was the major regulator of bone metabolism in women, with testosterone playing the analogous role in men. Subsequent studies established that complete sex steroid deficiency in either sex was associated with an activation of bone remodel-

Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved
Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031211

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.
ing (bone resorption and bone formation), but with a net deficit in bone formation relative to bone resorption and subsequent bone loss (Riggs et al. 2002). This review will delineate the evolution of our understanding of sex steroid regulation of bone metabolism, starting with human clinical—investigative and observational studies and then moving into data from mouse models. Although the human studies have provided important insights into physiology and the pathogenesis of osteoporosis, the mouse models have been instrumental in providing key mechanistic insights. Nonetheless, there are discrepancies between the human and mouse studies, and these will be highlighted where appropriate, with suggestions for potential resolutions to disparate findings. Although there is correlative evidence for relationships between weak adrenal androgens (Khosla et al. 1998) or progesterone (Prior 1990) and bone mineral density (BMD), direct evidence from interventional studies in humans is inconsistent for these steroids, so the focus will be on estrogen and testosterone effects on bone.

HUMAN STUDIES

Evidence from Estrogen Receptor—or Aromatase-Deficient Males

The traditional notion that estrogen was the dominant sex steroid regulating bone metabolism in women, whereas testosterone played the analogous role in men was challenged by the description in 1994 of the skeletal phenotype of a 28-year-old male with homozygous mutations in the estrogen receptor (ER)α gene, resulting in a nonfunctional ER (Smith et al. 1994). Despite normal testosterone and elevated estrogen levels, this individual had unfused epiphyses and osteopenia, with a spine BMD that was more than two standard deviations (SDs) below the mean for 15-year-old boys (the patient’s bone age). Subsequent to this report, two males with complete deficiency of the enzyme responsible for the final step in the synthesis of estrogens, aromatase, were described (Carani et al. 1997; Bilezikian et al. 1998) with a virtually identical skeletal phenotype to the ERα-deficient male. These “experiments of nature” clearly showed that, even in boys, estrogen was essential for epiphyseal closure and for the acquisition of bone mass during puberty in males. A subsequent description of a transiliac crest bone biopsy of the ERα-deficient male showed reduced cancellous bone volume and cortical width (Smith et al. 2008). Interestingly, in contrast to estrogen-deficient women or hypogonadal men who typically have increased bone remodeling (Riggs et al. 2002), the ERα-deficient male had markedly reduced indices of bone resorption and formation. This suggests the possibility that loss of the ligand (estrogen) may lead to reduced bone mass through a different mechanism than loss of the receptor. Indeed, this possibility is supported by numerous ligand-independent effects of ERα in bone and other tissues (Ciana et al. 2003). However, cultured bone marrow stromal cells from the ERα-deficient male also showed increased ERβ levels by Western analysis (Smith et al. 2008). The role of ERβ in bone metabolism is discussed later in greater detail in the mouse models, but at least in this human case report the high circulating estrogen and increased bone ERβ levels could not compensate for loss of ERα to preserve bone mass. Whether the low bone turnover with loss of ERα was because of the absence of ligand-independent effects of ERα or some degree of compensatory suppression of bone turnover because of the activation of ERβ by the elevated circulating estrogen levels remains unclear and warrants further mechanistic studies using mouse models.

Observational Studies

Extensive studies in women through the menopausal transition have confirmed Fuller Albright’s original observations regarding the key role of estrogen in regulating bone metabolism in women. Specifically, as shown in Figure 1, the decline in serum estradiol levels (and accompanying increase in serum follicle stimulating hormone [FSH] levels) through menopause is closely associated with an increase in osteoclastic bone resorption (urine N-telopeptide of type I collagen [NTx]) (Sowers et
al. 2013). Conversely, because the postmenopausal ovary continues to produce androgens, serum testosterone or other androgen levels do not change significantly across menopause (Handelsman et al. 2016), arguing against a role for androgens in contributing to postmenopausal bone loss. Moreover, the specific role, if any, of the relatively low circulating androgen levels in women in regulating bone metabolism has been difficult to identify in human studies and will be considered further in the mouse models discussed later.

Numerous observational studies in men have documented that, consistent with the findings from the ERα- and aromatase-deficient males, serum estrogen levels were more closely correlated with BMD and bone turnover markers than were serum testosterone levels. Using a population-based age-stratified sample of 346 men aged 23–90 years (Khosla et al. 1998), we found that serum total testosterone and estrogen (estradiol + estrone) levels decreased over the life span by 30% and 12%, respectively, but the bioavailable (or non-sex-hormone-binding globulin-bound) testosterone and estrogen levels decreased by 64% and 47%, respectively. Using multivariate analyses, serum bioavailable estrogen level was the consistent independent predictor of BMD in men. Thus, serum bioavailable estrogen levels not only declined significantly with age in men, but also correlated with declining BMD levels, suggesting that estrogen deficiency with aging may contribute to bone loss not only in women, but also in men. Since these original findings, numerous subsequent analyses have confirmed the closer association of BMD and rates of bone loss with serum bioavailable estrogen as compared with testosterone levels in men (for review, see Khosla et al. 2008).

**Interventional Studies**

The evidence from interventional studies is overwhelming that estrogen is the dominant sex steroid regulating bone metabolism in women. The most rigorous demonstration of this comes from the results of the Women's Health Initiative, which randomized 16,608 postmenopausal women aged 50 to 79 years to receive conjugated equine estrogen (0.625 mg/d) and medroxyprogesterone acetate (to prevent endometrial hyperplasia, 2.5 mg/d) or placebo for an average of 5.6 years (Cauley et al. 2003). Estrogen treatment increased BMD at multiple skeletal sites as compared with placebo and also reduced hip fracture risk by 33%. In contrast to estrogen, evidence that the low circulating testosterone levels present in women have a significant impact on bone metabolism is weak or inconsistent (Raisz et al. 1996).

To directly compare estrogen versus testosterone effects on bone metabolism in men, we performed an interventional study in which endogenous estrogen and testosterone production were pharmacologically suppressed and physiological levels of each were maintained by exogenous replacement using estrogen and testosterone patches (Falahati-Nini et al. 2000). Following baseline measurements of bone resorption (urinary deoxypyridinoline [Dpd] and NTx) and bone formation (serum osteocalcin and amino-terminal propeptide of type I collagen [PINP]) markers, the men were randomized into four groups: group A (−T, −E) discontinued both patches; group B (−T, +E) discontinued the testosterone but remained on...
the estrogen patch; group C (+T, –E) discontinued the estrogen but remained on the testosterone patch; and group D (+T, +E) continued both patches. As shown in Figure 2A, significant increases in the bone resorption markers (urinary deoxypyridinoline [Dpd] and N-telopeptide of type I collagen [NTx]), and (B) bone-formation markers (serum osteocalcin and amino-terminal extension peptide of type I collagen [PINP]) in a group of elderly men (mean age 68 yr) made acutely hypogonadal and treated with an aromatase inhibitor (group A), treated with estrogen alone (group B), testosterone alone (group C), or both (group D). See text for details. Asterisks indicate significance for change from baseline: *P < 0.05; **P < 0.01; ***P < 0.001. (From Falahati-Nini et al. 2000; adapted, with permission, from the American Society for Clinical Investigation © 2000.)
formation, but with a net gap between resorption and formation and ongoing bone loss (Riggs et al. 2002).

The findings from this study were largely confirmed more recently by Finkelstein and colleagues (Finkelstein et al. 2016) who used a somewhat different study design involving pharmacological induction of hypogonadism in men followed by graded doses of testosterone replacement with or without an aromatase inhibitor. Similar to our earlier study, changes in bone resorption and formation markers were predominantly regulated by estrogen. Moreover, testosterone, in the absence of aromatization to estrogen, was unable to prevent decreases in BMD at multiple sites. Collectively, these two and additional interventional studies (reviewed in Khosla 2015) using variations of the approaches used in the studies described above now provide compelling evidence in humans that, in both women and men, estrogen is the dominant sex steroid regulating bone metabolism. However, testosterone likely does play an important role during growth and, directly or indirectly (via the growth hormone/insulin-like growth factor [IGF] system) (Almeida et al. 2017), contributes to the periosteal apposition that results in larger bones in men as compared with women. We will revisit the findings from this human study in light of more recent findings in mice using cell-specific deletion of the androgen receptor (AR), which may require a reinterpretation of the human data.

**Potential Mediators of Estrogen Action on Bone in Humans**

A limited number of interventional studies have addressed potential mechanisms or mediators of estrogen action on bone in vivo in humans. For example, based mainly on studies in ovariectomized rodents, a number of proinflammatory cytokines have been suggested as mediators of the effects of estrogen on bone resorption, with tumor necrosis factor (TNF)-α and interleukin (IL)-1β being perhaps the most consistent estrogen-regulated cytokines in the rodent models (for review, see Weitzmann and Pacifici 2006). To address this issue in humans, we designed a study using estrogen withdrawal followed by blockade of either TNF-α or IL-1β action in postmenopausal women (Charatcharoenwitthaya et al. 2007). Specifically, postmenopausal women were treated with estrogen for 60 days followed by discontinuation of the estrogen for 3 weeks in the setting of either saline injections (control), treatment with a TNF-α blocker (etanercept), or an IL-1β blocker (anakinra). Because of the risk of infection, both blockers could not be used together in humans. As shown in Figure 3, the increase in bone resorption in the control women was significantly blocked (by ~50%) by the TNF-α blocker and to a lesser extent by the IL-1β blocker, showing that in humans TNF-α and perhaps IL-1β mediate the antiresorptive effects of estrogen on bone. In this model, neither...
blocker was able to prevent the decrease in bone formation following estrogen withdrawal, indicating that the maintenance of bone formation by estrogen was likely independent of these cytokines.

Another key factor regulating osteoclast development is receptor activator of nuclear factor κB (RANK) ligand (RANKL) produced by a number of cells in the bone microenvironment, including osteocytes and osteoblast lineage cells (for review, see Kearns et al. 2008). Indeed, RANKL is both necessary and sufficient for osteoclast differentiation given permissive concentrations of macrophage colony-stimulating factor (M-CSF), and it also enhances the activity and prolongs the life span of osteoclasts by decreasing apoptosis. To address the issue of estrogen regulation of RANKL, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces using flow cytometry and the decoy RANKL receptor, osteoprotegerin (OPG), as a probe (OPG-Fc-FITC) (Eghbali-Fatourechi et al. 2003). The marrow cells were characterized as osteoblast lineage, T cells, or B cells by using antibodies against bone alkaline phosphatase, CD3, and CD20, respectively, in premenopausal women, untreated postmenopausal women, or estrogen-treated postmenopausal women. We found that the fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in the estrogen-deficient postmenopausal women as compared with the premenopausal women by two- to threefold for each of the cell populations, and these increases were reversed by estrogen treatment (Fig. 4). These data show that, directly or indirectly, estrogen deficiency increases RANKL production by a number of cell populations in the bone microenvironment, contributing to the increase in bone resorption. Notably, the increased bone resorption in postmenopausal women can now be entirely reversed clinically by treatment with denosumab, a human monoclonal antibody to RANKL (Cummings et al. 2009).

There is also considerable evidence from human studies that estrogen regulates the production of the proposed inhibitor of Wnt signaling, sclerostin (Drake and Khosla 2017). A number of studies have shown that treatment of postmenopausal women with estrogen (Modder et al. 2011a,b; Fujita et al. 2014; Farr et al. 2015) or with the selective ER modulator, raloxifene (Chung et al. 2012), reduces circulating sclerostin levels using several different assays for sclerostin. Because there is some question as to whether serum sclerostin levels reflect changes in the bone microenvironment, we

![Figure 4](https://www.cshperspectives.org/content/cshperspect.a031211.Figure4.jpg)

**Figure 4.** Effects of estrogen on cell surface receptor activator of nuclear factor κB ligand (RANKL) expression in postmenopausal women. Changes in osteoprotegerin (OPG)-Fc-FITC fluorescence as an index of mean RANKL surface concentration per cell are shown for premenopausal women (red bars), estrogen-deficient postmenopausal women (green bars), and estrogen-treated postmenopausal women (black bars). (A–D) The various cell populations as indicated. P-values by analysis of variance (ANOVA) are as indicated. ***P < 0.001 versus the premenopausal women. (From Eghbali-Fatourechi et al. 2003; reproduced, with permission, from the American Society for Clinical Investigation © 2003.)
recently examined bone sclerostin messenger RNA (mRNA) levels in needle bone biopsies from either untreated or estrogen-treated postmenopausal women (Farr et al. 2015). Consistent with decreases in serum sclerostin levels using two different assays, bone sclerostin mRNA levels were also 41% and 48% lower when assessed by RNaseq and QPCR, respectively, in the estrogen-treated versus control women. Estrogen treatment also reduced bone mRNA levels of the sclerostin-related protein, sclerostin-containing protein 1 (SOSTDC1), which is also an inhibitor of Wnt- and BMP-signaling (Fujita et al. 2014). Given increasing evidence that sclerostin modulates not only bone formation, but also bone resorption (Tu et al. 2015), these findings suggest that sclerostin may be in the pathway of estrogen action on bone, as shown further by the mouse models discussed later. Moreover, similar to the translation of RANKL inhibition to a new therapeutic, sclerostin inhibition using a humanized monoclonal antibody, romosozumab (Cosman et al. 2016), results in a profound increase in bone formation and reduction in bone resorption in postmenopausal women, qualitatively similar to the pattern of changes in bone turnover induced by estrogen treatment (Drake and Khosla 2017).

**MOUSE MODELS**

**Deletion of ER or AR in Bone Cells**

The effects of estrogen on bone are mediated by two related, but distinct, receptors, ERα and ERβ (Almeida et al. 2017). Although the role of ERα in regulating bone metabolism in mice has been much more extensively studied than that of ERβ, our understanding even of ERα action on bone is still far from complete. Sims and colleagues (2002) initially studied mice with global deletion of ERα that had high circulating estrogen levels in females and increased testosterone levels in females and males. Deletion of ERα in either sex led to a decrease in bone turnover and increase in cancellous bone mass, but a decrease in cortical thickness. This indicated that, in cancellous bone, activation of ERβ by the high estrogen levels or the AR by the high testosterone levels in females was able to compensate for loss of ERα in cancellous but not cortical bone. Similarly, the high testosterone levels in males were able to compensate for loss of ERα in cancellous but not cortical bone. Deletion of ERβ did not alter sex steroid levels in either sex, had no effect on bone in males, and led to a decrease in bone resorption and increase in cancellous bone volume but not in cortical thickness in females at 10 weeks of age. In contrast, a subsequent study by Windahl and colleagues (1999) did find an increase in periosteal and endosteal circumference in female ERβ knockout mice. Thus, although the global ER-deletion models were confounded by altered sex steroid levels in the ERα knockout mice, they did show that (1) loss of ERα compromised cortical bone thickness in both sexes, and (2) ERβ did not regulate bone metabolism in males but could either compensate for loss of ERα in females, at least in the setting of elevated estrogen levels, or when ERα was present, ERβ appeared to antagonize ERα action on bone.

Similar to the global ERα knockout mice, male mice with global deletion of AR were found to have significant alterations in circulating sex steroid levels, specifically, reduced serum testosterone levels (Yeh et al. 2002; Kawano et al. 2003). Thus, although male AR knockout mice had reduced cancellous and cortical bone volume because of increased bone resorption, it is unclear whether this was the result of loss of the AR in bone cells or the concomitant hypogonadism. In contrast to male AR knockout mice, female AR knockout mice did not have any skeletal deficits.

Although these global ER and AR knockout mice provided some insights, more conclusive data on the roles of these receptors in bone metabolism has come from studies using Cre/LoxP technology for cell-specific deletions. Although the original description by Oursler and colleagues of the presence of ERs in avian (Oursler et al. 1991) and human (Oursler et al. 1994) osteoclasts and effects of estrogen on directly inhibiting osteoclast activity had been met with some skepticism, recent cell-specific ERα deletions, in fact, point to the osteoclast as...
Interestingly, the microarchitecture at 4, 8, 12, or 26 weeks of age. this Cre model showed deficits in bone mass or female nor male mice with ER\textsubscript{\alpha} et al. 2013) but perhaps, surprisingly, neither differentiation using the Ctsk-Cre (Nakamura et al. 2007) led to reductions in cancellous bone mass because of increased osteoclast numbers and high levels of bone resorption, but only in female mice. In contrast, AR deletion in myeloid cells using the LysM-Cre did not alter cancellous or cortical bone in either sex (Ucer et al. 2015). Thus, ER\textsubscript{\alpha} is critical for directly regulating osteoclast number and bone resorption in female but not male mice, and the AR does not appear to directly regulate osteoclasts in either sex.

A number of studies have used osteoblast lineage Cre models to delete sex steroid receptors at various stages of osteoblast differentiation. Deletion of ER\textsubscript{\alpha} in mesenchymal progenitors (using Prx1-Cre) or in osteoprogenitors (using Osx-Cre) impaired Wnt/\beta-catenin signaling, reducing proliferation and differentiation of periosteal cells (Almeida et al. 2013). This signaling pathway was important for optimal cortical bone accrual in females with a transient effect in males, but did not require the presence of estrogen (i.e., was a ligand-independent effect of ER\textsubscript{\alpha}). In contrast to cortical bone, deletion of ER\textsubscript{\alpha} using either the Prx1-Cre or Osx-Cre had minimal or no effect in cancellous bone in either sex (Almeida et al. 2013).

ER\textsubscript{\alpha} has also been deleted later in osteoblast differentiation using the Col1a1-Cre (Almeida et al. 2013) but perhaps, surprisingly, neither female nor male mice with ER\textsubscript{\alpha} deletion using this Cre model showed deficits in bone mass or microarchitecture at 4, 8, 12, or 26 weeks of age. Interestingly, the ER\textsubscript{\alpha};Col1a1-Cre mice did show an increase in osteoblast apoptosis in cancellous bone, but this did not translate into structural alterations in bone. In contrast to these findings using the Col1a1-Cre, studies using Cre models activated even later in osteoblast differentiation (i.e., in the late osteoblast/osteocyte) have generally found a reduction in bone mass in both sexes associated with low bone-formation rates, although the data are somewhat inconsistent. Thus, two studies used the osteocalcin (Ocn)-Cre and found deficits in cancellous and in cortical bone associated with reduced cancellous bone formation rates in female mice (Maatta et al. 2013; Melville et al. 2014). Although these deficits were present in female mice at 3–4 months of age, they appeared to take longer to develop in male mice and only became evident at 6 months of age.

Studies using the Dmp1-Cre, which overlaps with the Ocn-Cre but is expressed perhaps somewhat later in osteoblast differentiation, have yielded somewhat conflicting results. Thus, Windahl et al. (2013) reported that male but not female mice with ER\textsubscript{\alpha} deletion using the Dmp1-Cre had reduced cancellous bone mass associated with decreased bone formation. In contrast, Kondoh et al. (2014) found the opposite—reduced cancellous bone mass and decreased bone formation in female but not male mice. Cortical bone was unaffected in either sex in both studies. The reasons for these discrepant findings are unclear, but the collective findings using the Ocn- and Dmp1-Cre models do indicate that ER\textsubscript{\alpha} signaling is likely important in mature osteoblasts/osteocytes and that ER\textsubscript{\alpha} regulates bone formation, at least in part through regulating osteoblast apoptosis.

Cell-specific deletion of ER\textsubscript{\beta} either in osteoprogenitor cells (Prx1-Cre) or in more mature osteoblasts (Col1a1-Cre) has been shown to have the opposite effect to ER\textsubscript{\alpha} deletion, namely, an increase in cancellous bone mass but without an alteration in cortical bone mass in female mice (Nicks et al. 2016). This compartment-specific effect of ER\textsubscript{\beta} deletion (i.e., an increase in cancellous but not cortical bone mass) is of interest, as previous studies in human (Bord et al. 2001) and mouse (Modder et al. 2004) bone have found that both ER\textsubscript{\alpha} and ER\textsubscript{\beta} are expressed in cancellous bone, whereas cortical bone mainly contains ER\textsubscript{\alpha}. In addition, ex vivo studies found an increase in the ratio of colony-forming unit osteoblasts (CFU-OBs) to CFU fibroblasts (CFU-Fs) in the ER\textsubscript{\beta}-deleted mice, indicating increased differentiation of osteoblast precursor cells into osteoblasts in the absence of ER\textsubscript{\beta}. Consistent with findings in reproductive tissues (Hall and McDonnell
1999), ERβ was shown to antagonize ERα action in osteoblastic cells (Nicks et al. 2016). Thus, ERβ likely plays an antagonistic role to ERα in bone, and this effect is predominant in cancellous bone. This point will be considered further below in attempting to understand the compartment-specific effects of sex steroids in females and males.

In contrast to the absence of skeletal effects of AR deletion in myeloid/osteoclast lineage cells, deletion of the AR in osteoprogenitor cells (Prx1-Cre) resulted in osteopenia and increased bone resorption in cancellous, but not in cortical, bone in male mice, with female mice having a much milder but qualitatively similar phenotype (Ucer et al. 2015). Very similar findings were reported using the Col1a1-, Ocn-, and Dmp1-Cre mice crossed with floxed AR mice (Notini et al. 2007; Chiang et al. 2009; Sinnerseel et al. 2012), establishing the consistency of this observation across osteoblast lineage Cre models. Moreover, these unequivocal effects of AR signaling in cancellous bone in male mice appear to be at odds with the clear evidence from human studies noted earlier that estrogen is the dominant regulator of bone metabolism in men. This apparent discrepancy between the mouse and human data will be considered below.

Table 1 attempts to summarize the now extensive body of work from multiple laboratories regarding global, osteoblast-, or osteoclast-lineage deletion of ERα, ERβ, or AR. Keeping in mind that not all of the data are consistent across laboratories, the table presents the overall picture that is emerging. Thus, although global ERα deletion is confounded by profound alterations in circulating sex steroid levels, both female and male ERα knockout mice do have reductions in cortical bone mass. The most unequivocal findings are the following: (1) ERα deletion in osteoclasts leads to reduced cancellous (but not cortical) bone mass in females, but not males; (2) AR deletion in osteoblast lineage cells leads to reduced cancellous (but not cortical) bone mass in males, with a milder phenotype in females; and (3) ERβ deletion in osteoblast lineage cells leads to increased cancellous (but not cortical) bone mass in females. ERα deletion in osteoblast lineage cells has generally resulted in reductions in cancellous and perhaps cortical bone mass in females and cancellous bone mass in males, but these findings have been somewhat variable across laboratories. However, an important caveat to all of these studies is that the receptor deletion, although cell-specific, has been present since conception. As such, the skeletal findings reflect largely developmental effects of these receptors rather than their role in the adult skeleton. Further studies using both cell- and temporalspecific deletion of these receptors using inducible models are needed to address this limitation and further clarify the role of sex steroid receptors on the adult murine skeleton. In addition, for each of these receptor deletions, the severity of the published phenotypes depends on the

### Table 1. Summary of effects of deletion of sex steroid receptors, either globally or in specific cells, on bone mass

<table>
<thead>
<tr>
<th>Receptor deleted</th>
<th>Global</th>
<th>Osteoblast lineage/osteocyte</th>
<th>Myeloid/osteoclast</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cancellous</td>
<td>Cortical</td>
<td>Cancellous</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERα</td>
<td>↑</td>
<td>↓</td>
<td>(↓)</td>
</tr>
<tr>
<td>ERβ</td>
<td>↑</td>
<td>↔</td>
<td>↑</td>
</tr>
<tr>
<td>AR</td>
<td>↔</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERα</td>
<td>↑</td>
<td>↓</td>
<td>(↓)</td>
</tr>
<tr>
<td>ERβ</td>
<td>↔</td>
<td>↔</td>
<td>NT</td>
</tr>
<tr>
<td>AR</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
</tbody>
</table>

Parentheses surrounding arrows indicate somewhat conflicting data, with the overall evidence pointing to the direction noted.

NT, Not tested.
efficiency of deletion of the gene as well as the specificity of the deletion in the particular cell type, which is not always clearly assessed in the original papers.

**ERα Deletion in the Central Nervous System**

As shown by the above studies, ERα clearly has direct effects on bone, acting to preserve or enhance bone mass. In contrast, several studies indicate that this positive peripheral effect of ERα may be counterbalanced by a negative central effect. Thus, deletion of ERα in the central nervous system (CNS) using the nestin-Cre resulted in an increase in cancellous and cortical bone mass in female mice associated with increased bone formation (Ohlsson et al. 2012). The CNS ERα knockout mice had normal sex steroid, serotonin, and catecholamine levels, but did have increased serum leptin levels. Generally similar findings were noted in a subsequent study using POMC-Cre mice, in which the ERα deletion was more specific for hypothalamic neurons (Farman et al. 2016). Although this negative central effect of estrogen signaling on bone is of interest, the net effect of estrogen deficiency in mice and humans is bone loss, arguing that the peripheral effects of ERα signaling dominate over these negative central effects.

**Role of T and B Cells**

A series of studies, principally in mice, have provided substantial evidence for an important role of T cells in mediating ovariectomy-induced bone loss. The fundamental observation is that ovariectomy leads to an increase in TNF-producing T cells, which in turn results in an increase in RANKL-induced osteoclast formation (for review, see Pacifi 2012). A number of mechanisms have been proposed for the expansion of TNF-producing T cells, including increased antigen presentation, stimulation of IL-7 and interferon (IFN)-γ production, and down-regulation of transforming growth factor (TGF)-β production (Pacifi 2012). Activated T cells also increase RANKL and M-CSF production by bone marrow stromal cells through CD40L and DLK1/FA-1 (Pacifi 2012). A further intriguing aspect of this work has been the recent evidence linking sex steroid deficiency in mice to gut microbiota (Li et al. 2016). Specifically, sex steroid deficiency appears to lead to increased gut permeability, an expansion of Th17-activated T cells, and subsequent up-regulation of osteoclastogenic cytokines, including TNF-α, RANKL, and IL-17. Remarkably, germ-free mice lacking an intestinal microbiome are resistant to sex steroid deficiency-induced cancellous bone loss. This area is not without some controversy, however, as various mouse strains lacking T cells do lose cancellous bone following ovariectomy (Lee et al. 2006). In addition, mice lacking RANKL specifically in T cells lose bone similar to control mice following ovariectomy (Nakashima et al. 2011; Onal et al. 2012).

There is also evidence linking B cells to ovariectomy-induced bone loss in mice. Specifically, deletion of RANKL from B cells prevents cancellous bone loss and increased bone resorption following ovariectomy in mice (Onal et al. 2012). Ovariectomy increases the number of B cells (Masuzawa et al. 1994), although, in humans, estrogen deficiency may also increase RANKL expression per cell on B cells (Eghballi-Fatourechi et al. 2003). However, the precise mechanisms by which estrogens or androgens control B-cell numbers remain unclear at this point.

**Potential Mediators of Estrogen Action from Mouse Models Relative to Findings in Humans**

As noted earlier, there is relative consistency between the mouse data showing an important role for TNF-α in mediating ovariectomy-induced bone loss in mice (Weitzmann and Pacifi 2006) and human studies using the TNF-α blocker (etanercept) (Charatcharoenwitthaya et al. 2007). Estrogen deficiency also leads (directly or indirectly) to increased RANKL production by a number of cells, or an expansion of cells expressing RANKL, in the bone microenvironment in mouse models (Pacifi 2012), again generally consistent with...
human studies showing increased RANKL expression on bone marrow stromal cells, T cells, and B cells in estrogen deficient as compared with estrogen-sufficient women (Eghbali-Fatourechi et al. 2003). The human studies showing regulation of circulating sclerostin and bone SOST mRNA levels by estrogen (Modder et al. 2011a,b; Fujita et al. 2014; Farr et al. 2015) are also consistent with studies in mice with Lrp5 mutations rendering them resistant to sclerostin (Niziolek et al. 2015). These mice have absent or markedly attenuated bone loss following ovariectomy, indicating a potential role for sclerostin in mediating estrogen-deficiency bone loss. The suppression of SOSTDC1 mRNA levels in bone in postmenopausal women treated with estrogen (Fujita et al. 2014) is also consistent with the observation that mice with osteocyte-specific deletion of ERα have increased bone sostdc1 mRNA levels (Kondoh et al. 2014), although a causative role for sostdc1 in facilitating or mediating estrogen deficiency—induced bone loss remains to be established. ERα deletion in mesenchymal/stromal cells has also been shown to increase the expression of SDF1 and MMP13 (Ucer et al. 2016), which may play a role in mediating increased endocortical bone resorption following estrogen deficiency. However, these findings have not yet been validated in human studies.

**DISCREPANCIES BETWEEN THE HUMAN AND MOUSE STUDIES AND POSSIBLE RESOLUTIONS**

Although there generally are consistencies between the human and mouse data regarding sex steroid action on bone, and the mouse studies have been instrumental in defining the specific roles of ERα, ERβ, and AR in bone metabolism, there is a fundamental discrepancy between the human and mouse models that needs to be resolved. As noted earlier, the collective evidence from both the observational and interventional human studies is overwhelming that estrogen plays a much more significant role in regulating bone metabolism in men than testosterone (for review, see Khosla et al. 2008). In contrast, four separate studies in mice, discussed above, have found that AR deletion in osteoblast lineage cells in male mice leads to reduced cancellous bone volume and cancellous number associated with increased osteoclast numbers (Notini et al. 2007; Chiang et al. 2009; Sinnesael et al. 2012; Ucer et al. 2015). Moreover, neither AR nor ERα deletion has any effect on cortical bone in male mice.

One possibility is that mice may be fundamentally different from humans, at least in terms of sex steroid regulation of male bone. This may be a result of the fact that aromatase expression in rodents is predominantly in the brain and gonads, whereas humans have extensive aromatase expression across tissues (Simpson et al. 1997). On the other hand, it may be that the original interpretation of the human data (including by our group) was incomplete, particularly in light of the subsequent findings in mice. Thus, in our original human study using depletion of sex steroids and selective replacement with estrogen or testosterone (Falahati-Nini et al. 2000), we did observe a small increase in NTx in the −T, +E group (Fig. 2A), which represented ∼30% of the NTx increase observed after complete sex steroid deficiency. In light of the mouse findings, this increase, which was not suppressible by estrogen, likely represents the loss of the direct effects of testosterone (without aromatization to estrogen) on bone resorption in cancellous bone. In this interpretation, the bulk of the effects of estrogen in human males may well be in cortical bone, which is fundamentally different in humans versus mice. Specifically, humans have extensive intracortical, osteonal remodeling that is absent in mice (Jikla 2013). Thus, consistent with the findings in the AR deletion mouse models, testosterone (in the absence of aromatization to estrogen) likely does regulate cancellous bone resorption in humans, but the regulation of cortical bone remodeling by estrogen is much more evident in human versus mouse males because of the fundamental differences in cortical bone between the species. Moreover, because ∼80% of the skeleton is cortical bone (Bonnick 1998), estrogen inevitably emerges as the more dominant regulator of bone metabolism in human males.
Based on these considerations, Figure 5 attempts to synthesize the findings from the human and mouse models and presents a working hypothesis for the compartment-specific effects of estrogens versus androgens on bone in females and males. As described earlier, the major effect of castration in either sex is an increase in bone remodeling, with bone resorption outstripping bone formation, leading to bone loss. Thus, sex steroids collectively restrain the activation of bone remodeling, likely through effects on osteocytes, although this needs additional experimental validation using inducible deletion of sex steroid receptors in adult mice. As noted earlier, the distribution of ERα versus ERβ appears to be quite different in cancellous and cortical bone, with both receptors expressed in cancellous bone and ERα predominating in cortical bone. Because ERβ antagonizes ERα in bone (Nicks et al. 2016) and other tissues (Hall and McDonnell 1999), a plausible hypothesis that is supported by human (Khosla et al. 2011) and mouse (Syed et al. 2010) data is that it would take higher levels of estrogen to suppress bone remodeling in cancellous as compared with cortical bone. In females (Fig. 5A), estrogen levels are sufficiently high so that estrogen consistently suppresses bone remodeling in cancellous as compared with cortical bone. Females (Fig. 5A), estrogen levels are sufficiently high so that estrogen consistently suppresses bone remodeling in cancellous as compared with cortical bone. Males, however, have much lower estrogen levels, which are able to suppress cortical bone remodeling and perhaps have some effects in cancellous bone, but males require substantial androgen action in cancellous bone to adequately restrain bone remodeling and prevent bone loss in that compartment as adults (Fig. 5B). Although lacking experimental proof in all aspects, this formulation is nonetheless consistent with the available data discussed in this perspective and does reconcile the seemingly disparate findings from humans versus mice, keeping in mind the fundamental difference in intracortical remodeling between species.

SUMMARY AND CONCLUSIONS

Since the original description by Fuller Albright of the effects of estrogen deficiency on bone in women (Albright 1940), there has been enormous progress in our understanding of sex steroid regulation of the skeleton. Studies in humans and mice have generally been concordant and helped define the target cells, the roles of ERα, ERβ, and AR, and potential mediators of estrogen action on bone, albeit with less information on downstream targets of androgen action. The importance of estrogen action on bone is reflected by the fact that it is a key regulator of bone metabolism not only in women but also in men. Moreover, two of the new drugs developed in recent years for the treatment of osteoporosis, denosumab and romozosumab, target RANKL and sclerostin, respectively—molecules that in humans and in mice have been implicated in mediating, at least in part, estrogen action on bone. Thus, continuing to better define the mechanisms of sex steroid action on bone will not only provide fundamental knowledge regarding the regulation of bone

**Figure 5.** Working model to explain the differential effects of estrogen versus testosterone on cancellous and cortical bone. Please see text for further details. ER, Estrogen receptor; AR, androgen receptor.
metabolism, but likely also identify additional therapeutic targets to treat osteoporosis.

ACKNOWLEDGMENTS

This work is supported by National Institutes of Health (NIH) Grants P01 AG004875, AG048792, AR027065, and AR068275.

REFERENCES


Kearns AE, Khosla S, Kostenuik PJ. 2008. Receptor activator


Sex Steroids and Bone


Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031211